Home › NCT06123026

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial

Who can join

Ages 18 to 50 · Women · Healthy volunteers welcome

Inclusion Criteria:

* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
* ages 18 to 50
* con provide informed consent in English

Exclusion Criteria:

* Age under 18 or above 50
* gestational ages before 16 weeks 0 days or after 20 weeks 0 days
* unable to provide written consent in English
* hypertensive disorder
* uncontrolled hypertension or known hypersensitivity to ergot derivatives
* History of cardiac valvular disorders
* history of pulmonary fibrosis
* documented bipolar schizophrenia
* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)

About the study

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

What is being tested

• Cabergoline (drug)
• Placebo (drug)

Sponsor: Northwestern University · Participants: 200 · Started: Dec 18, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT06123026

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.